-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $40

Benzinga·08/13/2026 20:23:52
语音播报
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $43 to $40.